eligibility_summary
Eligible: histologically confirmed recurrent/metastatic pancreatic cancer with progression after ≥1 standard therapy (RECIST v1.1), ECOG 0–2, no surgery/radiation/immunotherapy within 4 weeks, recovered from side effects, and consented. Exclude: other cancer within 3 yrs (except non‑melanoma skin), prior anti‑tumor immunotherapy/related trials, active autoimmune disease needing immunosuppression, prior organ/HSCT transplant, active infections needing systemic treatment, or otherwise unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: 1) Autologous bone marrow–derived dendritic cell vaccine (CellgramDC‑WT1), generated from CD141+ DCs, type: cellular immunotherapy. 2) Pembrolizumab, type: anti–PD‑1 monoclonal antibody immune checkpoint inhibitor. Mechanisms: The DC vaccine is designed to present the WT1 tumor antigen and cross-prime CD8+ T cells, driving WT1‑specific cytotoxic responses against pancreatic cancer cells. Pembrolizumab blocks PD‑1 on T cells, preventing PD‑L1–mediated inhibitory signaling and restoring T‑cell effector function. Cells/pathways targeted: CD8+ T cells and dendritic cells, WT1‑expressing tumor cells, PD‑1/PD‑L1 checkpoint pathway within the tumor immune microenvironment.